The Food and Drug Administration (FDA) recently approved a new, non-opioid (non-narcotic) prescription pill, suzetrigine (SUE ...

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

Pershing is hopeful it’ll make an impact in reducing addiction but wants to see the new drug in use before casting a final judgment. “When oxycodone was released, Purdue Pharma told everyone this was ...

The FDA's landmark approval of Journavx (suzetrigine)?the first non-opioid pain reliever in over two decades?represents a breakthrough in pain management. This breakthrough underscores the urgent need ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...